Breast ultrasound in the management of gynecomastia in Peutz–Jeghers syndrome in monozygotic twins: two case reports

Graziella Di Grezia1*, Tiziana Romano2, Francesco De Francesco3, Francesco Somma1, Gaetano Rea4, Roberto Grassi1 and Gianluca Gatta1

Abstract

Introduction: Peutz–Jeghers syndrome is an autosomal dominant disease with incomplete penetrance and variable expression caused by germline mutation of serine threonine kinase 11/liver kinase B1; it is characterized by hamartomatous polyps in the gastrointestinal tract, mucocutaneous melanin pigmentation, and increased predisposition to neoplasms. In Peutz–Jeghers syndrome, bilateral Sertoli cell testicular tumors cause endocrine manifestations including gynecomastia and feminization. This study aimed to assess the role of breast ultrasound in the evaluation of the effectiveness of an innovative surgical approach.

Case presentation: This report presents a pair of European 9-year-old identical male twins with Peutz–Jeghers syndrome, bilateral prepubertal gynecomastia, and testicular multifocal calcifications. Both twins were treated with anastrozole for 2 years. After finishing treatment, both underwent subcutaneous mastectomy performed by the “modified” Webster technique. Breast examination and ultrasound were performed before and after the pharmacological and surgical treatment. A breast ultrasound scan before surgery showed bilateral gynecomastia in both patients. No solid nodular or cystic formations were present on either side. After pharmacological therapy and surgical glandular removal, a breast examination showed a significant reduction in breast volume; 1 year after surgery, a breast ultrasound scan of both patients showed a total absence of glandular parenchyma, with muscle planes well represented.

Conclusions: Breast examination and ultrasound have proved to be a valid approach in the assessment of the treatment of prepubertal gynecomastia because they allow the efficacy of the pharmacological and surgical treatment to be evaluated in a multidisciplinary approach to one of the most frequent endocrine manifestations of Peutz–Jeghers syndrome.

Keywords: Breast ultrasound, Gynecomastia, Peutz–Jeghers, Subcutaneous mastectomy

Introduction

Peutz–Jeghers syndrome (PJS) is an autosomal dominant disease with incomplete penetrance and variable expression [1,2] caused by germline mutation of serine threonine kinase 11 (STK11/liver kinase B1, LKB1) [3,4].

It is characterized by increased predisposition to neoplasms [5] and hamartomatous polyps in the gastrointestinal tract, and mucocutaneous melanin pigmentation with high phenotypic variability. In PJS, high aromatase activity [6] causes oversecretion of estrogen by bilateral Sertoli cell testicular tumors (large-cell calcifying tumors) with advanced bone age, feminization and gynecomastia.

Gynecomastia is a benign condition characterized by enlargement of the male breast due to proliferation of glandular tissue; it is common in normal males during the neonatal period, at early puberty, and with increasing age. Prepubertal gynecomastia is characterized by the presence of palpable un- or bilateral breast tissue in boys without other signs of sexual maturation. It could be related with excessive estrogen production by adrenal or testicular...
tumors [7-9], also in rare syndromes such as PJS, congenital adrenal hyperplasia, or overexpression of aromatase or to the use of drugs that affect androgen and estrogen production and metabolism. This case report describes the role of breast ultrasound in the surgical management of prepubertal gynecomastia and subsequent follow-up in monozygotic twins with PJS and bilateral multifocal testicular calcifications.

Case presentation
A pair of European 9-year-old identical male twins (patients 1 and 2) with PJS presented with bilateral progressive prepubertal gynecomastia over the course of 1 year. The family history showed that their father had PJS but no history of gynecomastia or testicular calcification. Neither mutations nor deletions were found in the tumor suppressor gene LKB1/STK11, which is responsible for approximately 60% of PJS cases.

The twins arrived at our Department in 2008. A physical examination showed two boys with pigmented lesions of the lips and bilateral gynecomastia with a diameter of 9cm in patient 1 and 7cm in patient 2, corresponding to a female Tanner stage B3. Their testicular volume was 4mL bilaterally. The boys’ penises were infantile, and they had no pubic or axillary hair (pubic hair, PH1; genitalia development, G1).

The height of patient 1 was 129.2cm (25th percentile), with a growth velocity of 7cm/year (90th percentile for age) and normal weight for height. The height of patient 2 was 125.5cm (10 to 25th percentile), with a growth velocity of 6cm/year (75 to 90th percentile) and normal weight for height. The target height was 173cm (−0.7 Standard Deviation Score, SDS).

Hormonal treatment
Hematic levels of sexual hormones were constantly verified with specific reference to luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, testosterone, estrone and estradiol.

Baseline endocrine investigations in patients 1 and 2 showed normal prepubertal serum concentrations of testosterone, FSH, LH and dehydroepiandrosterone sulfate, as well as slightly elevated levels of estradiol, with normal levels of estrone.

Both boys were treated with the third-generation aromatase inhibitor, anastrozole, starting dose of 1mg orally once daily. The decision to treat the boys with the aromatase inhibitor anastrozole had been implemented to reduce gynecomastia and to prevent the accelerating effect of estrogen excess on skeletal maturation.

Samples were obtained before the beginning of the anastrozole treatment, then after 1 and 2 years of treatment, during 2-years follow-up evaluation, before and after 3 months subcutaneous mastectomy surgery.

During the period of anastrozole treatment, a reduction of gynecomastia was observed more in one twin than in the other. In particular, during the first year of treatment, growth velocity decreased from 7 to 3cm and gynecomastia decreased from 9 to 4cm in diameter in patient 1, whereas growth velocity decreased from 6.6 to 3cm/year and gynecomastia decreased from 7 to 3cm in diameter in patient 2.

During the second year of treatment, no changes in gynecomastia occurred, and growth velocity reverted to normal values for age in patient 1 (5cm/year), whereas it remained below the normal value for age in patient 2 (3.5cm/year).

After 2 years, a sharp reduction in growth velocity occurred for both patients (although it was more pronounced in patient 2, with a growth velocity of 1.6cm/year, 3rd percentile), which prompted a reduction in the anastrozole dose and then its withdrawal at the age of 11.5 years.

After a washout period of 6 months, clinical reevaluation of both twins showed regrowth of gynecomastia, corresponding to a female Tanner stage B3, with resumed tenderness of the breast to palpation (Table 1, Figure 1).

Bone age
To determine bone age, X-rays of each patient’s non-dominant hand and wrist were analyzed by the TW2 method before anastrozole treatment was started, and after 1 year of treatment and 2 years of treatment.

| Table 1 Breast ultrasound monitoring of gynecomastia and growth before treatment (enrollment), during 2 years of pharmacological treatment (first and second year), at pharmacological interruption (>2 years), and before and after surgical removal |
|-----------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Breast growth (cm/year)                      | Enrollment      | Pharmacological treatment | Pharmacological interruption | Before surgery | 1 month after surgery | 1 year after surgery |
|                                              |                 | First year | Second year | >2 years | 2 years | 6 months | 2 years | 6 months |
| Patient 1                                    | 7                | 3          | 5          | 5        | 6      | 0        | 0        |
| Patient 2                                    | 6.6              | 3          | 3.5        | 1.6      | 3.6    | 0        | 0        |
| Gynecomastia (cm)                            | Enrollment      | Pharmacological treatment | Pharmacological interruption | Before surgery | 1 month after surgery | 1 year after surgery |
|                                              |                 | First year | Second year | >2 years | 2 years | 6 months | 2 years | 6 months |
| Patient 1                                    | 9                | 4          | 4          | 4        | 5      | 0        | 0        |
| Patient 2                                    | 7                | 3          | 3          | 3        | 6      | 0        | 0        |
Bone age was 11.2 years in patient 1 and 10.9 years in patient 2, with an advance of approximately 2.5 years and an adult height prognosis of 157cm (−3 SDS) for patient 1 and 158.7cm (−2.8 SDS) for patient 2 (both below the target height).

**Ultrasound findings**

Ultrasound was performed using a Logiq S6 scanner (GE Healthcare, Waukesha, WI, USA) with a multifrequency matrix-array linear transducer (7 to 14MHz) and a multifrequency convex transducer (3.5 to 5MHz).

A breast ultrasound to assess palpable masses was performed during and after pharmacological treatment, before and after 1 month and 1 year from subcutaneous mastectomy surgery. The examinations showed bilateral gynecomastia with typical hyperechoic fibroglandular tissue. No solid nodular or cystic formations were present on either side.

An abdominal ultrasound scan of their adrenal glands and a testicular ultrasound scan were performed to analyze the presence of estrogen-producing adrenal tumor; a testicular ultrasound scan showed bilateral multifocal calcifications.

**Surgical treatment**

At the age of 13 years, the twins underwent gynecomastia surgical treatment, using the Webster technique. A skin incision was made below the areola edge and the adipose and glandular tissues were significantly removed under direct vision from the skin at the top and from the pectoral muscle at the bottom; the removed breast tissue was sent to a pathologist.

The result was radical surgery (thus avoiding recurrence) and a good aesthetic result.

In both boys, an advancement flap of adipose tissue below the nipple–areola complex was placed, in consideration of the underlying disorder, to avoid leaving a residual subareolar glandular parenchyma (Figures 2 and 3).

Although the glandular tissue had been completely removed, this technique allowed a good aesthetic result, thus avoiding depression of the nipple–areola complex, which would remain responsive to the circulating estrogen.
Both patients were satisfied with the result and had no functional impairment of their arms or reduction in nipple–areola complex sensitivity. Wound healing was completed in 10 days, and scars were almost undetectable in both cases. The excessive removal of parenchyma did not result in skin irregularities, avoiding any unnecessary subsequent treatment. Both patients received postoperative pain management with painkillers according to their weight. The clinical course had no irregularities. No surgical infections or hematomas were reported. Although the breast gland had been totally removed, both patients had good cutaneous retraction and no nipple or areola necrosis or deformity, as confirmed by ultrasound picture control.

Histologic findings confirmed their condition to be benign. After surgical glandular removal, a breast examination showed a significant reduction in breast volume; 1 year after surgery, a breast ultrasound scan of both patients showed a total absence of glandular parenchyma, with muscle planes well represented.

A compressive medication was applied after surgery with a chest bandage for 4 weeks.
Analgesics were prescribed only in case of pain. Both boys were observed by surgeons 1 and 4 weeks after surgery for removal of the bandage and to exclude the onset of hematomas, seromas, skin infections, keloids and pain.

Follow-up
After surgery, the twins were followed for an additional year for evaluation of sex hormone levels, growth curve and breast size.

Discussion
Gynecomastia is a multifactorial disease, primarily dependent on the balance between free estradiol and free testosterone. Estrogen biosynthesis results from the production of androgens from steroid precursors; therefore, an excess of endogenous estrogen can be a result of an increase in substrate, aromatase activity, or both.

An increase in the level of estrogen is the most common cause of imbalance. The most common causes of gynecomastia are endocrinopathies, neoplasm-producing estrogens, human chorionic gonadotropin or aromatase, hyperaromatase syndrome [6] and only few cases of idiopathic prepubertal disease. The frequencies of some remaining causes have been estimated as follows: cirrhosis (8%), primary hypogonadism (8%), testicular tumors (3%), secondary hypogonadism (2%), hyperthyroidism (1.5%), and renal disease (1%).

Testicular cancer (associated with both germ cell tumors and non-germ cell tumors) accounts for 1 to 1.5% of all male neoplasms. Although PJS represents one of the genetic conditions predisposing to these types of tumors, it remains a rare condition [10-13]. Our two patients with PJS with large-cell calcifying Sertoli cell tumors had prepubertal gynecomastia for approximately 1 year (Tanner stage 3) and had advanced bone age from the increased level of serum estradiol.

The treatment of prepubertal gynecomastia depends on its etiology. Medical therapy with an aromatase inhibitor alone is not effective in reversing prepubertal gynecomastia. The initial florid stage, characterized by ductal proliferation, can respond to medical treatment but, subsequently, glandular hyperplasia is replaced by progressive fibrosis and hyalinization; when it causes painful or psychological disturbance, surgical removal of the breast glandular tissue is indicated [10,14].

However, anastrozole represents the first noninvasive step of treatment in PJS and may be useful for delaying surgery in very young patients to achieve an optimal aesthetic result. Plastic surgeons used a standard mastectomy through a semicircular incision within the margin of the pigmented area of the areola to conceal the scar.
The standard technique included positioning a 5- to 7-
mm pad under the nipple to prevent dermal adherence to
the pectoralis fascia. To provide possible recurrence, they
totally removed the gland and set up an advancement flap
of adipose tissue to prevent adhesion of the nipple to the
pectoralis fascia and its unaesthetic depression.

In conclusion, gynecomastia is a multifactorial disorder,
and a correct evaluation must be performed to distinguish
physiologic and pathologic causes. The history must in-
clude testicular assessment symptoms of hepatic disease
and alcohol consumption as well as family history. Phys-
ical examination and a routine biochemical profile permit
an acknowledgement and recognition of most underlying
causes.

Conclusions

Although severe gynecomastia is a rare condition in the
pediatric age, competence and expertise is necessary for
the treatment of these patients. Breast examination and
ultrasound have proved to be a valid approach in the as-
sement of the treatment of prepubertal gynecomastia
because they allow the efficacy of the pharmacological
and surgical treatment to be evaluated in a multidiscipli-
nary approach to one of the most frequent endocrine
manifestations of PJS.

Consent

Written informed consent was obtained from the patients’
mother for publication of this case report and accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.

Abbreviations

FSH: Follicle-stimulating hormone; LH: Luteinizing hormone; PJS: Peutz-Jeghers
syndrome; SD5: Standard Deviation Score.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

GDG made substantial contributions to conception and design; TR made
substantial contributions to acquisition of data; DFD made substantial
contributions to analysis of data; FS agrees to be accountable for all aspects
of the work in ensuring that questions related to the accuracy or integrity of
any part of the work are appropriately investigated and resolved; GR made
substantial contributions to interpretation of data; RG gave final approval of
the version to be published; GG has been involved in drafting the
manuscript or revising it critically for important intellectual content. All
authors read and approved the final manuscript.

Acknowledgement

We are greatly indebted to Silvia Losco for language consultancy.

Author details

1 Department of Clinical and Experimental Medicine “F. Magrassi, A. Lanza”,
Section of Radiology and Radiotherapy, Second University of Naples, Naples,
Italy.
2 Pediatric Department, Second University of Naples, Naples, Italy.
3 Department of Orthopedic, Traumatologic, Rehabilitation, and
Plastic-Reconstructive Sciences, Second University of Naples, Naples, Italy.
4 Radiology Department, Monaldi Hospital, Ospedale dei Colli, Naples, Italy.

Received: 4 March 2014 Accepted: 6 October 2014
Published: 18 December 2014

References

1. CI A, Ball D, Thiel TJ, Anderson JP, Gourley L, Frazier ML, Lynch PM,
Luchtefeld MA, Young A, McGarity TJ, Selkin MF: Fine mapping of a
genetic locus for Peutz-Jeghers syndrome on chromosome 19p. Cancer
Res 1997, 57:3653–3656.
2. Hemminki A, Tomilinson I, Markie D, Jänvien H, Sistonen P, Björkqvist AM,
Knuutila S, Salovaara R, Bodmer W, Shibata D, De la Chapelle A, Aaltonen
LA: Localization of a susceptibility locus for Peutz-Jeghers syndrome to
19p using comparative genomic hybridization and targeted linkage
analysis. Nat Genet 1997, 15:38–43.
3. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Müller O,
Back W, Zimmer M: Peutz-Jeghers syndrome is caused by mutations in a
novel serine threonine kinase. Nat Genet 1998, 18:38–43.
4. Jiang CY, Esufali S, Berk T, Gallinger S, Cohen Z, Tobin M, Redston M, Bapat B:
STK11/LKB1 germline mutations are not identified in most Peutz-Jeghers
syndrome patients. Clin Genet 1999, 56:136–141.
5. Gardiello FM, Trimbath JD: Peutz-Jeghers syndrome and management
recommendations. Clin Gastroenterol Hepatol 2006, 4:408–415.
6. Bulun SE, Noble LS, Takayama K, Michael MD, Agarwal V, Fisher C, Zhao Y,
Hinshelwood MM, Ito Y, Sippom ER: Endocrine disorders associated with
inappropriately high aromatase expression. J Steroid Biochem Mol Biol
1997, 61:133–139.
7. Itami RM, Amundson GM, Kaplan SA, Lippe BM: Prepubertal gynecomastia
caused by an adrenal tumor. Diagnostic value of ultrasonography. Am J
Dis Child 1982, 136:584–586.
8. Coen P, Kulin H, Ballantine T, Frauenhofer E, Boal D, Inkster S, Brodie A,
Santen R: An aromatase-producing sex-cord tumor resulting in prepubertal
gynecomastia. W Engl J Med 1991, 324:317–322.
9. Berenszttein E, Belgrosky A, de Davila MT, Rivarola MA: Testicular steroid
biosynthesis in a boy with a large cell calcifying Sertoli cell tumor
producing prepubertal gynecomastia. Steroids 1995, 60:220–225.
10. Kara C, Kutlu AO, Tosun MS, Ayapdin S, Senel F: Sertoli cell tumor causing
prepubertal gynecomastia in a boy with Peutz-Jeghers syndrome: the
outcome of 1-year treatment with the aromatase inhibitor testolactone.
Horm Res 2003, 60:252–256.
11. Gourgar E, Saloustros E, Stratakis CA: Large-cell calcifying Sertoli cell
tumors of the testes in pediatrics. Curr Opin Pediatr 2012, 24:518–522.
Aesth Plast Surg.
12. Esposito V, Gatta G, Di Gresta G, Iaconino A, Fiumarella A, Russo A, Feragalli B,
Grassi R: Anatomical features of cephalothoracopagus variations: CT and
MRI. J Biol Regul Homeost Agents 2013, 27:2595–602.
13. Ferraro GA, Romano T, De Francesco F, Grandore A, D’Andrea F, Miraglia del
Giudice E, Cataldo C, Gatta G, Di Grezia G, Perreone L, Nicoletti G: Management
of prepubertal gynecomastia in two monозygotic twins with Peutz-Jeghers
syndrome: from aromatase inhibitors to subcutaneous mastectomy. Aesth
Plast Surg 2013, 37(5):1012–1022.
14. Davilla HL, Lay E: Current concepts in gynaecomastia. Surgeon 2009,
7:114–119.

doi:10.1186/1752-1947-8-440
Cite this article as: Di Gresta et al.: Breast ultrasound in the management of
gynecomastia in Peutz-Jeghers syndrome in monozygotic twins: two
case reports. Journal of Medical Case Reports 2014 8:440.